Cosmecca Korea Co (241710) Fair Value & Analysis
Consumer Defensive · KR · Market cap 751B KRW
Fair value as of: Jun 24, 2026
Analysis
Cosmecca Korea Co (241710) currently trades at 66,700 KRW, while our model-based Fair Value estimate is 89,348 KRW — implying the stock looks roughly 34.0% undervalued today. We read business quality at 80/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Cosmecca Korea Co., Ltd. engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally. It offers skincare products, including lotion/toner, cream, essence, cleansers, Korean herbal products, mask sheet, scalp care, home scents, body and bath, exfoliators, and treatment products, as well as products for men, babies, and children; functional skincare products, which includes brightening, wrinkle and fine line, UV blocks/sunscreen, tanning, multi-functional, hair and body, and acne care products; and makeup products, such as BB and CC cream, skin cover balms, makeup base, foundation, concealer, lipstick, mascara, eyeliner, eyeshadow, blush/highlighter, and powders. The company was incorporated in 1999 and is headquartered in Eumseong-eup, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Cosmecca Korea Co (241710) undervalued?
What is the fair value of 241710?
What is the quality score of 241710?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.